步骤详解!复合面部提升技术带来很好的亚洲人面部提拉效果

2022-01-01 MedSci原创 MedSci原创

面部组织提升技术主要分为两类:仅在SMAS层进行的解剖和提升技术;以及SMAS层以下解剖的深平面提升技术:复合皮瓣提升技术。

面部组织提升技术主要分为两类:仅在SMAS层进行的解剖和提升技术;以及SMAS层以下解剖的深平面提升技术:复合皮瓣提升技术。

随着对面部解剖学的理解不断进步,使得浅表肌肉腱膜系统(SMAS)解剖越来越安全,复合式面部整容术也越来越流行。

本文介绍了新加坡团队在亚洲患者中进行复合面部整容的技术,并回顾了他们的经验和结果。

图1 文章来源

研究者在2010年1月至2020年6月,对128名亚洲患者进行了复合式面部提升术。94例为一期整容,34例为二期或三期整容。

作者的手术技术和适应亚洲患者的具体要求进行了详细描述。

面部软组织分为五层:

  • 1.皮肤
  • 2.皮下组织
  • 3.SMAS层:主要分布于面颊外侧、眶周的眼轮匝肌及面颈前内侧的颈阔肌
  • 4.韧带及疏松间隙:司 固定及滑动
  • 5.深筋膜层:咀嚼肌、颞肌及咬肌表面的深筋膜及深层骨膜

图2、3 皮肤分层图解,年龄对比

第4层是复合浅筋膜和深筋膜与下方咀嚼器之间的自然滑动面。在年轻人中,这一层虽然允许移动,但很坚固且拉紧(左)。随着年龄的增长,由于松弛和组织松弛的倾向,面部软组织空间的顶部会出现扩张和下垂(右)。因此,由于这是随着年龄增长而形成的松弛的主要解剖部位,直接收紧浅筋膜是进行面部整容的最有效和最合理的方法。这也通过将浅筋膜恢复到年轻时的位置,实现了最自然、最和谐的面部年轻化

因此,切开第4层,拉动整个浅筋膜的复合皮瓣以实现面部提升技术叫做复合面部提升技术。

 

手术步骤主要为切口及标记、打开SMAS下的间隙及松解韧带(下咬肌前间隙)、去除多余的颊脂垫、打开颧前间隙、打开颈阔肌间隙,而后用3-0线提升下咬肌前间隙的顶层、上咬肌前间隙的顶层、颧弓韧带、颧弓间隙的顶层。

其中做切口时要注意:

切口注意隐蔽及无痕;画好过渡标记:从外眦至下颌角,二者平滑的连线即为过渡线;耳周切口处开始分离,起始层次为皮下组织层,沿SMAS层表面向前分离。

图4 步骤图解

此图显示了面部的第4层(亚SMAS)解剖结构。术者以三步方法松解SMAS。第第1步是在下表面进行解剖,通过释放分离下表面和上表面的固定韧带进入下表面和上表面的装配前间隙。较低的预装配空间最宽,最容易进入。然后打开上部空间,两个空间都缩回,它们之间的固定韧带可以急剧释放。在这里,面神经的下颊支在腮腺肉瘤筋膜下运行,因此保留韧带的释放应在软组织间隙顶部的高度进行。第2步通过眼轮匝肌下钝性剥离并打开颧前间隙,将剥离引导至松解的上部。钝性手指解剖可用于完全打开鼻唇皱襞的空间(FAME、手指辅助颧骨提升术、技术)。第3步是迅速释放颧骨保留韧带的关键步骤。因为这里没有面部软组织间隙,所以必须通过锐利的解剖来完成释放。为安全起见,将牵开器分别放置在该区域上方和下方颧前间隙和装配前间隙顶部下方的间隙中,以使颧骨韧带处于张力状态。由于神经位于解剖的底部,因此在离间隙顶部更近的高处进行释放,释放颧骨韧带,并在颧骨大肌上向鼻唇沟方向进行解剖,将神经安全地放在解剖的地板上。这种程度的释放允许面部复合皮瓣完全活动。

平均随访26个月(6-108个月)。脂肪移植是手术的一个组成部分,95%的患者同时接受面部脂肪移植和面部整容。

结果显示,大多数患者对该技术的美学效果表示高度满意,效果自然、持久。剥离的面部提升平面穿过面部软组织间隙,提供非创伤性SMAS下通路,精确释放中间的保留韧带,以有效移动皮瓣。通过强调复合皮瓣的张力而不是皮肤闭合处的张力,绝大多数患者的疤痕是离散的。并发症少,无血肿或皮瓣坏死。暂时性神经损伤率为1.5%,没有患者有永久性神经损伤。

综上述,复合式面部提升术是亚洲患者的理想技术,因为它能提供自然、持久的效果;迅速恢复;患者满意度高。

原始文章:

Wong Chin-Ho,Hsieh Michael Ku Hung,Mendelson Bryan,Asian Face Lift with the Composite Face Lift Technique.[J] .Plast Reconstr Surg, 2021, undefined: undefined.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-07 666lll

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-06 ms6000000487809205

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-05 奔袭

    厉害了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-05 ms6000000252543114

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-04 13642c4a4dm

    增长知识了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-02 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1181888, encodeId=ca14118188889, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f2e2531207, createdName=666lll, createdTime=Fri Jan 07 16:23:55 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181115, encodeId=49ec1181115fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcdb6159738, createdName=ms6000000487809205, createdTime=Thu Jan 06 00:18:55 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180791, encodeId=126c1180e91da, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abee5571249, createdName=奔袭, createdTime=Wed Jan 05 09:51:56 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180775, encodeId=81801180e75d3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=301c5482318, createdName=ms6000000252543114, createdTime=Wed Jan 05 08:41:55 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180605, encodeId=f420118060571, content=增长知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=073e4743015, createdName=13642c4a4dm, createdTime=Tue Jan 04 22:19:55 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179883, encodeId=8acd11e988343, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jan 02 23:08:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179701, encodeId=fa1811e970188, content=向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 02 07:44:37 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-02 查查佳佳

    向研究表明,在一次就诊时被确定为MCI的人中,有5%至53%在下一次就诊时不再

    0

相关资讯

ASJ:面部年轻化里的面部脂肪切除术如何定位比较合适?

面部男性化在寻求面部年轻化de 女性整容患者中很常见。有少部分患者,由于颊脂垫(BFP)比较突出,在下颌骨侧面显得比较臃肿。

自体富血小板浓缩物在面部年轻化中的应用

作者:顾娜,陈小平,南京医科大学附属友谊整形外科医院整形外科自体富血小板浓缩物(autologous platelet rich concentrate,APRC)是通过离心的方法从自体血中获取的血浆浓缩物,具有良好的组织修复和再生作用,已被广泛应用于面部年轻化的治疗中。笔者就APRC的主要制品和制备方法、生物学功能、在面部年轻化整形中的临床应用和展望综述如下。1.APR

PPDO线联合A型肉毒毒素及透明质酸用于面部年轻化中的效果观察

目前,临床主要通过注射A型肉毒毒素和透明质酸减轻动态性皱纹,改善面部结构。聚对二氧环已酮(PPDO)线是在人体内可被完全分解,近几年广泛应用于微创面部年轻化治疗中,其对面部松弛的提拉效果已被临床证实。但目前临床缺乏PPDO联合A型肉毒毒素和透明质酸在面部年轻化中的应用研究,为此,本研究对84例面部年轻化的女性进行分组研究,报道如下。

拓展阅读

面部提升用到的带刺聚二恶烷酮 (PDO) 缝合线安全吗?效果可以持续多久呢?

允许微创皮肤提升的带刺聚二恶烷酮 (PDO) 缝合线广泛且越来越多地用于美容皮肤病学。

内入路保留鼻整形丨歪鼻矫正+小切口面部提升

今天的这位主人公是位老师,暑假的时候特地从温州赶过来的,现在术后三个多月了,最近发来了反馈,想分享给大家。